Phaseline

Targets › KLF4

KLF4 (Krueppel-like factor 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.

Transcription factor; can act both as activator and as repressor. Binds the 5'-CACCC-3' core sequence. (UniProt, O43474)

Open in Phaseline: the race on KLF4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Life BiosciencesER-100
AAV-based epigenetic therapy delivering OSK transcription factors (OCT4, SOX2, KLF4) via i
OCT4, SOX2, KLF4Phase 1Open Angle Glaucoma (OAG)May 2027

Conditions

Open Angle Glaucoma (OAG) (1)

Modalities

other (1)

Companies

Life Biosciences (1)

Related targets

OCT4 (1) SOX2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.